针对近期司美格鲁肽相关失明诉讼热搜,科普「眼中风」NAION的病症特点,梳理不同研究的矛盾结论,厘清药物真实风险量级,给出用药人群实用的安全建议,避免盲目恐慌。
参考文献:
Hathaway JT, et al. Association of semaglutide with NAION. JAMA Ophthalmol. 2024(单中心,HR 4.28/7.64). DOI: 10.1001/jamaophthalmol.2024.3057
Cai CX, et al. Semaglutide and NAION (OHDSI, 3710万T2D). JAMA Ophthalmol. 2025;143(4):304-314. DOI: 10.1001/jamaophthalmol.2024.6555
NANOS & American Academy of Ophthalmology. GLP-1 RAs and Risk of NAION: Consensus Statement. 2026-05. https://www.aao.org/
Choi T, et al. GLP-1 RAs vs SGLT2 inhibitors and NAION risk (VA, 58.8万人). JAMA Netw Open. 2026-04-30.
Vilsbøll T, et al. NAION incidence across liraglutide/semaglutide RCTs(RCT汇总,诺和诺德). EASD 2025, LBA-25-3912.
EMA PRAC. NAION confirmed as a very rare side effect of semaglutide. 2025-06.